The Nottingham firm behind a revolutionary baby heartbeat monitoring device has landed a seven-figure cash injection to explore foreign markets and grow its product range.
SurePulse Medical, based at MediCity, has secured £1 million from existing and new private investors to support its growth plans.
Founded in 2014 as joint venture between the University of Nottingham and Derby-based electronics manufacturer Tioga, the company’s first product – the SurePulse VS – is the world’s only wireless heartrate monitor specifically designed for new-born babies.
READ MORE: {}
SurePulse VS was awarded its CE mark in 2019 and has been trialled in NHS hospitals on over 300 new-borns.
Now, thanks to its latest funding boost, SurePulse can start to explore more markets beyond the 海角视频, while also developing new products.
James Carpenter, chief executive of SurePulse, said: “Despite the uncertainty surrounding the coronavirus pandemic, investors continue to be upbeat about the long-term commercial potential of the business - and have reinforced this through the new investment.
“The need for innovative medical devices is more important than ever as our healthcare systems experience unprecedented pressure.
“This investment will help SurePulse to drive market share gains and continue its exciting product development plans.”
Most Read
The optical sensor technology underpinning the SurePulse VS hands-free baby heart monitor was developed in the Faculties of Engineering and Medicine at the University of Nottingham.
Professor Hayes-Gill, research director at SurePulse, said: “It is a great achievement to see a medical device that was designed and trialled by our collaborative research groups reach clinics around Europe.
“SurePulse is another spinout success story and one that aligns with the 海角视频 Government’s industrial strategy to commercialise research and deliver skills and jobs in STEM fields.”